Furthermore, EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event in type 2 diabetes mellitus) [11–13] and CANVAS (CANagliflozin cardioVascular Assessment Study) [14] have shown that treatment with SGLT-2 inhibitors may reduce cardiovascular morbidity and mortality, as well as the onset and/or progression of nephropathy in high-risk T2DM patients, when compared to standard care. The gene discussed is SLC5A2; the disease is Nephropathy.